A-101 Topical Solution
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Seborrheic Keratosis
Conditions
Seborrheic Keratosis
Trial Timeline
Mar 21, 2018 → Nov 14, 2018
NCT ID
NCT03487588About A-101 Topical Solution
A-101 Topical Solution is a approved stage product being developed by Aclaris Therapeutics for Seborrheic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03487588. Target conditions include Seborrheic Keratosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03487588 | Approved | Completed |
Competing Products
15 competing products in Seborrheic Keratosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elidel + Ketoconazole Cream | Novartis | Phase 2 | 52 |
| PF-07038124 + Placebo Ointment | Pfizer | Phase 2 | 51 |
| Ketoconazole | GSK plc | Approved | 84 |
| Azelaic Acid 15% Gel + Inactive 15% gel base | Bayer | Phase 2 | 49 |
| Ruxolitinib 1.5% Cream | Incyte | Phase 2 | 49 |
| Roflumilast Foam 0.3% + Vehicle foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| Roflumilast Foam + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
| ARQ-154 | Arcutis Biotherapeutics | Phase 2 | 47 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle | Aclaris Therapeutics | Phase 1/2 | 33 |
| A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution | Aclaris Therapeutics | Phase 2 | 44 |